Autonomous microfluidic electrochemical nano-biosensors for highly sensitive and selective detection and monitoring of biomarkers

目前，为快速检测生物流体标记物而开发的即时检测方法和设备至少面临着自动化、多路复用、定量测量、可重复性、可扩展性或成本方面的挑战。该项目旨在开发一种新的可扩展和可重复的毛细管微流体电化学纳米生物传感（CAMEN）平台，该平台可实现复杂定量生物分析的全自动，以实现低成本和即时检测生物标志物。目的1：研制可重复、超灵敏的电化学纳米生物传感器；目的2：毛细管微流控元件及CAMEN平台的开发；目的3：利用CAMEN平台检测加标/临床样品中的生物标志物。在两年结束时，我们将展示导电纳米材料/油墨的新成分的生产及其在柔性基板上的丝网印刷，使电极转化为电化学纳米生物传感器只需一步。该项目还将开发一种新的微流控平台，其中包含已开发的表征毛细管微流控元件库，一旦结合起来，就可以将复杂的电化学生物传感协议自动化到单个芯片上。我们提出的基于camen的生物检测将1)是自动化和定量的样品到结果测试，2)是模块化的，易于进行新的检测，3)具有多路复用能力，可以在一个试剂盒中同时检测各种类型的生物标志物，4)快速（<20分钟）和低成本（< 15-20美元），5)由于无线信号传输到Web-App和云系统而与数字健康监测兼容，符合加拿大新兴数字健康平台的需求。该项目将为加拿大在微纳米技术、诊断平台和医疗器械方面的产品和知识产权创造需求，从而为加拿大带来经济效益。

The present point-of-care assays and devices developed for rapid detection of biofluid markers are dealing with at least one of the challenges of automation, multiplexing, quantitative measurement, reproducibility, scalability, or cost. This project aims to develop a new scalable and reproducible CApillary Microfluidic Electrochemical Nano-biosensing (CAMEN) platform which enables full automation of complex quantitative bioassays for low-cost and point-of-care detection of biomarkers. Objective #1: Development of reproducible and ultrasensitive electrochemical nano-biosensors; Objective #2: Development of capillary microfluidic components and the CAMEN platform; Objective #3: Employment of the CAMEN platform for detecting biomarkers in spiked/clinical samples. At the end of the two years, we will demonstrate the production of novel compositions of conductive nanomaterials/inks and their screen-printing on flexible substrates, enabling the conversion of electrodes to electrochemical nano-biosensors in one single step. The project will also lead to the development of a new microfluidic platform with a developed library of characterized capillary microfluidic components, and once combined, can automate complex protocols of electrochemical biosensing into one single chip. Our proposed CAMEN-based bioassays would 1) be automated and quantitative sample-to-result tests, 2) be modular and easily adaptable for making new assays, 3) have multiplexing capability for detecting various types of biomarkers simultaneously in one single kit, 4) be rapid (<20 min) and low-cost (<$15-20), and 5) be compatible with digital health monitoring due to the wireless signal transfer to Web-App and Cloud-systems, aligned with the needs of emerging digital health platforms in Canada. This project will lead to economic benefits to Canada by creating demands for Canada's products and IPs related to micro- and nano-technologies, diagnostic platforms, and medical devices.